Subcutaneous · GLP-1 agonist
Visepegenatide
10 trials in this molecule. Source: ClinicalTrials.gov, as of November 5, 2026.
Trials
10
Ongoing
0
Recruiting
0
Completed
9
Sites
10
Countries
2
Endpoints
53
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
5
Phase 1/2
1
Phase 2
2
Phase 3
2
Trials by status
Completed
9
Unknown
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
21
Glycemic / diabetes
18
Weight & body composition
6
Other (unclassified)
6
Cardiometabolic biomarkers
2
Top 20 metrics across this asset's endpoints
AUC₀-∞Safety/PK
3
HbA1c, changeGlycemic
2
HbA1c <7.0% achievementGlycemic
2
Body weight, absolute change (kg)Weight
2
Fasting glucose, changeGlycemic
2
BMI, changeWeight
2
Treatment-emergent AEs (any)Safety/PK
1
Plasma concentration (steady state)Safety/PK
1
CmaxSafety/PK
1
TmaxSafety/PK
1
Half-lifeSafety/PK
1
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
10 of 10
Showing 1-10 of 10 trials